论文部分内容阅读
自1975年K(o|¨)hler和Milstein首次成功地将小鼠脾细胞与连续培养的骨髓瘤细胞株融合,创造杂交瘤技术以来,单克隆抗体(单抗)在肿瘤学领域内被广泛研究和应用。1979年Minna首先制备出抗人肺癌单抗。目前单抗在肺癌诊断和治疗方面的研究十分活跃。本文简要介绍有关进展及其前景。一、肺癌相关抗原单克隆抗体的制备应用杂交瘤技术制备肺癌单抗有三种途径。(1)利用已建立的人肺癌细胞株和小鼠B淋巴细胞瘤。Cu-ttita等用这种方法制备了主要与小细胞肺癌(SCLC)或非小细胞癌(NSCLC)反应的单抗。(2)用肿瘤分泌产物作为确定抗原。已知肺癌能分泌癌胚抗原(CEA)和B绒毛膜性腺激素,也已制备出这些
Since the first time in 1975 Köhler and Milstein succeeded in fusion of mouse spleen cells with a continuous cultured myeloma cell line, the monoclonal antibody (monoclonal antibody) has been widely used in oncology since the creation of hybridoma technology. Research and application. In 1979 Minna first prepared anti-human lung cancer monoclonal antibody. At present, monoclonal antibodies are active in the diagnosis and treatment of lung cancer. This article briefly describes the progress and prospects. I. Preparation of monoclonal antibodies for lung cancer-associated antigens There are three ways to prepare monoclonal antibodies against lung cancer using hybridoma technology. (1) Use established human lung cancer cell lines and mouse B lymphoma cells. Cu-ttita et al. used this method to prepare a monoclonal antibody that reacts mainly with small cell lung cancer (SCLC) or non-small cell carcinoma (NSCLC). (2) Using tumor secreted products as a definitive antigen. Lung cancer is known to secrete carcinoembryonic antigen (CEA) and B chorionic gonadotropin, and these have also been prepared.